Data show clear evidence of anti-tumor activity and durable partial and complete responses in heavily pre-treated patients with tumors that progressed through checkpoint inhibitors AU-007’s unique ...

ATP and Biolojic Design have teamed up to create IL-2-focused cancer biotech Aulos Bioscience. The startup begins life with IL-2-binding monoclonal antibodies designed by Biolojic Design and a $40 ...

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today ...

LARKSPUR, Calif., March 25, 2025--(BUSINESS WIRE)--Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics ...

US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as Bavencio by its original developer Merck KgaA ...

Aulos Bioscience’s cancer therapy, imneskibart, could enter a registrational study either in melanoma, non-small cell lung cancer (NSCLC) or both, as soon as 2026. Speaking to Clinical Trials Arena, ...

Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting Aulos Bioscience, ...

BOSTON and TEL AVIV, Israel, March 15, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as ...

The 'aulos' in the Ure Museum is the best known example of a popular musical instrument from ancient Greece. Although it looks like a flute, our single pipe was actually half of a double aulos, a wind ...

Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer ...